Venus Remedies Gains New Drug Approvals in Vietnam

Venus Remedies, one of the world’s top 10 manufacturers of fixed-dosage injectable drugs, has received new marketing authorizations in Vietnam for three key products  methotrexate, cefuroxime, and irinotecan. These latest approvals strengthen the company’s growing presence in South Asia’s dynamic pharmaceutical market, bringing its total number of active product registrations in Vietnam to 29.

The new authorizations highlight Venus Remedies’ expanding role as a trusted Indian supplier of high-quality critical care injectables. With over 374 marketing approvals already secured across the ASEAN region, the company continues to enhance the availability of advanced therapies while reinforcing India’s reputation as a dependable source of pharmaceuticals.

Also Read: Omega Hospitals Acquires Cytecare to Expand Cancer Network

Commenting on the development, Saransh Chaudhary, President of Global Critical Care at Venus Remedies and CEO of Venus Medicine Research Centre, stated, “Our expansion reflects a steadfast commitment to making advanced critical care treatments accessible in emerging markets. Southeast Asia is a key focus for us, and we aim to strengthen our presence through continuous product diversification and sustainable collaborations.”

Vietnam, currently India’s 15th largest trading partner and one of its top four pharmaceutical destinations in Southeast Asia, has witnessed steady growth in bilateral pharmaceutical trade over the past five years.

This growth is driven by rising demand for complex generics, oncology solutions, and antimicrobial therapies. With the ASEAN pharmaceutical market expected to reach USD 63.5 billion by 2029, the region remains an essential pillar of India’s global pharmaceutical trade strategy.